RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
BioCryst
Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced that Jon
Stonehouse, President and Chief Executive Officer of BioCryst, plans
to provide a corporate summary and update regarding the Company's
clinical programs at the Bank of America Merrill Lynch Healthcare
Conference in Las Vegas on Tuesday, May 10, 2011 at 2:20 p.m. Pacific
Time.
Links to a live audio webcast and replay of the presentation may be
accessed on the BioCryst website at www.BioCryst.com.
About BioCryst
BioCryst Pharmaceuticals designs, optimizes and develops novel
small-molecule pharmaceuticals that block key enzymes involved in
infectious diseases, inflammatory diseases and cancer. BioCryst
currently has three novel late-stage compounds in development: peramivir,
a neuraminidase inhibitor for the treatment of influenza, BCX4208,
a purine nucleoside phosphorylase (PNP) inhibitor for the treatment of
gout, and forodesine, an orally-available PNP inhibitor for hematological
malignancies. Utilizing crystallography and structure-based drug design,
BioCryst continues to discover additional compounds and to progress
others through pre-clinical and early development to address the unmet
medical needs of patients and physicians. For more information, please
visit the Company's website at www.biocryst.com.
This press release contains forward-looking statements, including
statements regarding future results and achievements. These statements
involve known and unknown risks, uncertainties and other factors which
may cause our actual results, performance or achievements to be
materially different from any future results, performances or
achievements expressed or implied by the forward-looking statements.
Please refer to the documents BioCryst files periodically with the SEC
and located at http://investor.shareholder.com/biocryst/sec.cfm.
BCRXW
BioCryst Pharmaceuticals
Robert Bennett, +1-919-859-7910
Source: BioCryst Pharmaceuticals, Inc.
News Provided by Acquire Media